Literature DB >> 16736180

Vincristine-induced neuropathy in rat: electrophysiological and histological study.

Feras M H Ja'afer1, Farqad B Hamdan, Faiq H Mohammed.   

Abstract

Peripheral sensory-motor neuropathy is one of the most frequent side effects of vincristine (VCR) administration, which often limits its usefulness in the treatment of a wide range of neoplastic diseases. The purpose of this work is to study VCR neurotoxicity in experimental animals from clinical, electrophysiological, and histological points of view. Sixty-five rats were used as a control group and 31 rats were divided into two groups and given VCR in two different regimens: the fixed-dose group (0.2 mg/kg) and the increasing-dose group (0.1 mg/kg, by an increment of 0.05 mg/kg/week). VCR was given intraperitoneally once weekly for five consecutive weeks. Electrophysiological examinations of the control and both treated groups were performed and included measurements of nerve conduction velocity and action potential (AP) amplitude of sciatic and tail nerves weekly during the period of treatment and 14 weeks after discontinuation of treatment. Histological sections of sciatic nerves were examined after the appearance of early electrophysiological changes, at the end of the 5th, and 19th weeks of the study (14 weeks after discontinuation of treatment). With the progress of the treatment, an increasing number of rats showing signs of neurological deficits were observed. During the first 5 weeks of this study, electrophysiological testing showed a nonsignificant difference in the conduction velocities of sciatic and tail nerves between the control and the treated groups, whereas a significant decrease in the amplitude of the sensory nerve action potential (SNAP) and compound muscle action potential (CMAP) of the tested nerves was recorded. The reduction in the AP amplitude was associated with histological changes characterized by axonal degeneration with relative demyelination. Fourteen weeks after discontinuation of treatment, a significant increment in the SNAP and CMAP amplitudes of both sciatic and tail nerves was noticed. While the CMAP amplitude of the distal segment of the tail showed nonsignificant increment, lesser number of fibers with axonal and/or myelin lesions were found. The clinical, electrophysiological, and histological results suggest that VCR induces peripheral sensorimotor neuropathy of axonal type more prominent in the fixed- than the increasing-dose group. The discontinuation of VCR permitted the improvement of the electrophysiological and histological changes. The rat can be used as an animal model for studying VCR neurotoxicity. However, further studies on larger number of animals are required to evaluate the type of nerve fiber involvement and the site of damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16736180     DOI: 10.1007/s00221-006-0499-2

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  38 in total

1.  Mononeuropathy due to vincristine toxicity.

Authors:  L P Levitt; D Prager
Journal:  Neurology       Date:  1975-09       Impact factor: 9.910

Review 2.  Peripheral neurotoxic disorders.

Authors:  M B Bromberg
Journal:  Neurol Clin       Date:  2000-08       Impact factor: 3.806

3.  Vincristine treatment of advanced cancer: a cooperative study of 392 cases.

Authors:  J F Holland; C Scharlau; S Gailani; M J Krant; K B Olson; J Horton; B I Shnider; J J Lynch; A Owens; P P Carbone; J Colsky; D Grob; S P Miller; T C Hall
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

4.  Vinblastine and vincristine: a study of their action on tissue concentrations of epinephrine, norephinephrine and acetylcholine.

Authors:  D L Cheney; I Hanin; R Massarelli; M Trabucchi; E Costa
Journal:  Neuropharmacology       Date:  1973-03       Impact factor: 5.250

5.  The effect of vincristine on nerve regeneration in the rat. An electrophysiological study.

Authors:  S Shiraishi; P M Le Quesne; T Gajree
Journal:  J Neurol Sci       Date:  1985-11       Impact factor: 3.181

6.  Nerve conduction impairment in experimental diabetes-proximodistal gradient of severity.

Authors:  J Patel; D R Tomlinson
Journal:  Muscle Nerve       Date:  1999-10       Impact factor: 3.217

7.  Ganglioside treatment of vincristine-induced neuropathy. An electrophysiologic study.

Authors:  G Favaro; F Di Gregorio; C Panozzo; M G Fiori
Journal:  Toxicology       Date:  1988-05       Impact factor: 4.221

8.  Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans.

Authors:  K O Aley; D B Reichling; J D Levine
Journal:  Neuroscience       Date:  1996-07       Impact factor: 3.590

9.  A study of the effects of isaxonine on vincristine-induced peripheral neuropathy in man and regeneration following peripheral nerve crush in the rat.

Authors:  P M Le Quesne; C J Fowler; A E Harding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-09       Impact factor: 10.154

10.  High incidence of vincristine-induced neuropathy in lymphomas.

Authors:  S M Watkins; J P Griffin
Journal:  Br Med J       Date:  1978-03-11
View more
  10 in total

1.  Atorvastatin prevents the development of diabetic neuropathic nociception by possible involvement of nitrergic system.

Authors:  Reyhaneh Akbarian; Mohsen Chamanara; Amir Rashidian; Alireza Abdollahi; Shahram Ejtemaei Mehr; Ahmad Reza Dehpour
Journal:  J Appl Biomed       Date:  2021-02-09       Impact factor: 1.797

2.  Dapsone improves the vincristine-induced neuropathic nociception by modulating neuroinflammation and oxidative stress.

Authors:  Sevda Shayesteh; Mina Khalilzadeh; Nasrin Takzaree; Ahmad Reza Dehpour
Journal:  Daru       Date:  2022-09-15       Impact factor: 4.088

3.  Neuroprotective Effect of Matrine in Mouse Model of Vincristine-Induced Neuropathic Pain.

Authors:  Shuai-Shuai Gong; Yu-Xiang Li; Meng-Ting Zhang; Juan Du; Peng-Sheng Ma; Wan-Xia Yao; Ru Zhou; Yang Niu; Tao Sun; Jian-Qiang Yu
Journal:  Neurochem Res       Date:  2016-08-25       Impact factor: 3.996

Review 4.  Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy.

Authors:  Jordi Bruna; Paola Alberti; Aina Calls-Cobos; Martial Caillaud; M Imad Damaj; Xavier Navarro
Journal:  Exp Neurol       Date:  2019-12-15       Impact factor: 5.330

5.  Neuroprotective Effect of Anethole Against Neuropathic Pain Induced by Chronic Constriction Injury of the Sciatic Nerve in Mice.

Authors:  Bing Wang; Guoxin Zhang; Mei Yang; Ning Liu; Yu-Xiang Li; Hanxiang Ma; Lin Ma; Tao Sun; Huanran Tan; Jianqiang Yu
Journal:  Neurochem Res       Date:  2018-10-26       Impact factor: 3.996

6.  Comparative Analysis of Chemotherapy-Induced Peripheral Neuropathy in Bioengineered Sensory Nerve Tissue Distinguishes Mechanistic Differences in Early-Stage Vincristine-, Cisplatin-, and Paclitaxel-Induced Nerve Damage.

Authors:  Kevin J Pollard; Brad Bolon; Michael J Moore
Journal:  Toxicol Sci       Date:  2021-02-26       Impact factor: 4.849

Review 7.  Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN).

Authors:  Yaqin Han; Maree T Smith
Journal:  Front Pharmacol       Date:  2013-12-18       Impact factor: 5.810

Review 8.  A Mechanistic Understanding of Axon Degeneration in Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Yusuke Fukuda; Yihang Li; Rosalind A Segal
Journal:  Front Neurosci       Date:  2017-08-31       Impact factor: 4.677

9.  Effects of chemotherapy for acute lymphoblastic leukemia on cognitive function in animal models of contemporary protocols: A systematic literature review.

Authors:  Tyler C Alexander; Kevin R Krull
Journal:  Neurosci Biobehav Rev       Date:  2021-08-03       Impact factor: 9.052

10.  Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy.

Authors:  Naoto Okada; Takeshi Hanafusa; Takumi Sakurada; Kazuhiko Teraoka; Toshihide Kujime; Masahiro Abe; Yasuo Shinohara; Kazuyoshi Kawazoe; Kazuo Minakuchi
Journal:  J Clin Med Res       Date:  2014-05-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.